Business
PAOG Cites New British Medical Journal Case Report On CBD Lung Cancer And COPD Treatment As Validation Of PAOG Ongoing RespRx Drug Research
PAOG Cites New British Medical Journal Case Report On CBD Lung Cancer And COPD Treatment As Validation Of PAOG Ongoing RespRx Drug Research.
About this update from Pao Group, Inc.
[{"type":"text","content":"\n\n\n\nPAOG Cites New British Medical Journal Case Report On CBD Lung Cancer And COPD Treatment As Validation Of PAOG Ongoing RespRx Drug Research\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nPAOG Cites New British Medical Journal Case Report On CBD Lung Cancer And COPD Treatment As Validation Of PAOG Ongoing RespRx Drug Research\nPR Newswire\nSANDUSKY, Ohio, Oct. 15, 2021\n\n\n\nSANDUSKY, Ohio, Oct. 15, 2021 /PRNewswire/ -- PAO Group, Inc. (USOTC: PAOG) cited a British Medical Journal case study report published today on the effectiveness of CBD in the treatment of lung cancer and COPD as validation of PAOG's ongoing research and development of its own respiratory disorder treatment under the name RespRx.\nLast year, PAOG acquired intellectual property derived through research into CBD extracted in association with a patented extraction method (U.S. Patent No. 9,199,960).  The ongoing research targets the treatment of respiratory disorders in support of a pharmaceutical being developed by PAOG under the name RespRx.\nPAOG has engaged Veristat as a CRO to prepare an IND for the FDA.\nPAOG's RespRx research has shown effectiveness in the treatment of Chronic Obstructive Pulmonary Disease (COPD) and other similar respiratory conditions. \nThe British Medical Journal (BMJ) today released a report on a case study where CBD demonstrated effectiveness in the treatment of lung cancer and COPD.\nRespRx, in addition to its clinical research with COPD, has been engaged in select, non-clinical trials to treat cancer and demonstrated effectiveness.\nIn conjunction with PAOG's ongoing IND initiative for RespRx, and PAOG's connection with U.S. Patent No. 9,199,960 entitled \"METHOD AND APPARATUS FOR PROCESSING,\" PAOG is now receiving unsolicited contacts expressing interests ranging from investment and partnership to acquisition.\nPAOG is not altering its plans at this stage in reaction to the recent interest.  The company will continue developing its pharmaceutical and nutraceutical treatments.\nPAOG expects to realize its first CBD nutraceutical product sale...